PDCD1 and neoplasm: To understand the underlying mechanisms driving the enhanced anti-tumour response induced by treatment with the anti-PD-1 and anti-TIGIT antibody combination, an additional mouse experiment was conducted to monitor infiltrations of T and NK immune cells.